# Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

> **NCT06087068** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 140 (estimated)

## Conditions studied

- Thyroid Cancer
- Surgery
- Recurrence

## Interventions

- **DRUG:** Thyroxine

## Key facts

- **NCT ID:** NCT06087068
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087068, "Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06087068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*